Graft vs Host Disease

• 

  Subject Areas on Research

  • A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. 
  • A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. 
  • A clinical review: cutaneous manifestations of acute and chronic graft-versus-host disease following bone marrow transplantation. 
  • A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. 
  • A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation. 
  • A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. 
  • A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. 
  • A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases. 
  • A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. 
  • A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. 
  • A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. 
  • A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. 
  • A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. 
  • A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. 
  • A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia. 
  • A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. 
  • A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. 
  • A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. 
  • A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. 
  • Aberrant B-cell homeostasis in chronic GVHD. 
  • Acute and chronic graft-versus-host disease in man. 
  • Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens. 
  • Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. 
  • Acute graft-versus-host disease: are we close to bringing the bench to the bedside? 
  • Acute graft-vs-host disease: pathobiology and management. 
  • Acute myelogenous leukemia associated with Ollier disease. 
  • Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. 
  • Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease. 
  • Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. 
  • Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning. 
  • Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. 
  • Advances in pediatric hematopoietic stem cell transplantation. 
  • Advances in the understanding and treatment of human severe combined immunodeficiency. 
  • Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma. 
  • Alemtuzumab for the prevention and treatment of graft-versus-host disease. 
  • Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study. 
  • Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. 
  • Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. 
  • Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. 
  • Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. 
  • Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. 
  • Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. 
  • Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. 
  • Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. 
  • Allogeneic marrow transplantation. 
  • Allogeneic memory T cell response. 
  • Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. 
  • Allogeneic small bowel transplantation with cyclosporine and donor whole-body irradiation. 
  • Allogeneic splenocyte transfer and lipopolysaccharide inhalations induce differential T cell expansion and lung injury: a novel model of pulmonary graft-versus-host disease. 
  • Allospecific CD4(+) effector memory T cells do not induce graft-versus-host disease in mice. 
  • Alterations in natural anticoagulant levels during allogeneic bone marrow transplantation: a prospective study in 27 patients. 
  • Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. 
  • Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. 
  • Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. 
  • Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. 
  • Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. 
  • An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. 
  • Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. 
  • Antibodies are back for thymic attack in cGVHD. 
  • Antigen-specific T-lymphocyte function after cord blood transplantation. 
  • Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. 
  • Appearance of multiple benign paraproteins during early engraftment of soy lectin T cell-depleted haploidentical bone marrow cells in severe combined immunodeficiency. 
  • Are there effective new strategies for the treatment of acute and chronic GvHD? 
  • Association of IL-1β -511 polymorphism with severe veno-occlusive disease in pediatric-matched allogeneic hematopoietic stem cell transplantation. 
  • Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. 
  • Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. 
  • Autologous serum eye drops for severe dry eye syndrome in a patient with chronic graft-versus-host disease: a case report. 
  • B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. 
  • B cells in chronic graft-versus-host disease. 
  • B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. 
  • B-cell targeting in chronic graft-versus-host disease. 
  • Biomarkers in chronic graft-versus-host disease: quo vadis? 
  • Blazing a new TRAIL in hematopoietic cell transplantation. 
  • Bone density loss during treatment of chronic GVHD. 
  • Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development. 
  • Bone marrow transplantation for sickle cell disease. 
  • Bone marrow transplantation for sickle cell disease. The United States experience. 
  • Bone marrow transplantation for thalassemia. The USA experience. 
  • Bone marrow transplantation in patients aged 45 years and older. 
  • Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. 
  • Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. 
  • Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial. 
  • Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. 
  • Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. 
  • Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. 
  • Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. 
  • Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. 
  • Changing trends in marrow transplantation for aplastic anemia. 
  • Children Receiving Hematopoietic Stem Cell Transplantation are at Increased Risk of Onychocryptosis Requiring Surgical Management. 
  • Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. 
  • Chronic Graft-versus-Host Disease: A Long Road Ahead. 
  • Chronic cutaneous graft-versus-host disease in man. 
  • Chronic graft-versus-host disease and other late complications of bone marrow transplantation. 
  • Chronic graft-versus-host disease, obliterative bronchiolitis, and graft-versus-leukemia effect: case histories. 
  • Chronic graft-versus-host disease. 
  • Chronic graft-versus-host disease. 
  • Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. 
  • Cirrhosis of the liver in long-term marrow transplant survivors. 
  • Clinical applications for biomarkers of acute and chronic graft-versus-host disease. 
  • Clinical intestinal transplantation: new perspectives and immunologic considerations. 
  • Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. 
  • Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. 
  • Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. 
  • Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. 
  • Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. 
  • Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. 
  • Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. 
  • Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. 
  • Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. 
  • Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. 
  • Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. 
  • Complete DiGeorge syndrome: persistence of profound immunodeficiency. 
  • Complications of allogeneic bone marrow transplantation. 
  • Composite tissue allotransplantation: current challenges. 
  • Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. 
  • Consensus diagnostic histopathological criteria for acute gastrointestinal graft versus host disease improve interobserver reproducibility. 
  • Conventional B cells, not B1 cells, are the source of autoantibodies in chronic graft-versus-host disease. 
  • Cord blood stem cells. 
  • Cord-blood engraftment with ex vivo mesenchymal-cell coculture. 
  • Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. 
  • Coronary artery occlusion secondary to graft versus host disease after bone marrow transplant in a 21-year-old. 
  • Correction of chronic granulomatous disease after second unrelated-donor umbilical cord blood transplantation. 
  • Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. 
  • Critical assessment of automated flow cytometry data analysis techniques. 
  • Current status of bone marrow transplantation. 
  • Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. 
  • Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. 
  • Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. 
  • Cyclosporine treatment of chronic graft-versus-host disease following allogeneic bone marrow transplantation. 
  • Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. 
  • Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. 
  • Depletion of host reactive T cells by photodynamic cell purging and prevention of graft versus host disease. 
  • Dermatomal sclerodermoid graft-vs-host disease following varicella-zoster virus infection. 
  • Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. 
  • Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease. 
  • Diagnostic challenge in recurrent skin rash after autologous bone marrow transplantation. 
  • Direct ultrastructural evidence of target-directed polarization by cytotoxic lymphocytes in lesions of human graft-vs-host disease. 
  • Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease. 
  • Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. 
  • Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers. 
  • Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. 
  • Donor immune reconstitution after liver-small bowel transplantation for multiple intestinal atresia with immunodeficiency. 
  • Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. 
  • Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience. 
  • Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. 
  • Durable engraftment and correction of hematological abnormalities in children with congenital amegakaryocytic thrombocytopenia following myeloablative umbilical cord blood transplantation. 
  • Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. 
  • Early and late interstitial pneumonia following human bone marrow transplantation. 
  • Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. 
  • Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. 
  • Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. 
  • Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. 
  • Effects of treatment regimens on post marrow transplant relapse. 
  • Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. 
  • Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. 
  • Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. 
  • Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. 
  • Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. 
  • Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. 
  • Ex vivo spermine dialdehyde treatment prevents lethal GVHD in a murine bone marrow transplantation model. 
  • FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. 
  • Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia. 
  • Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors. 
  • Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands. 
  • Flow cytometric detection of lymphocyte proliferation in eyes with immunogenic inflammation. 
  • Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. 
  • Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. 
  • Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. 
  • Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. 
  • Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. 
  • Further examination of BAFF SNPs in cGVHD. 
  • Gastric graft-versus-host disease: a blinded histologic study. 
  • Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. 
  • Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. 
  • Graft vascular disease after cardiac transplantation and its relationship to mean acute rejection score. 
  • Graft versus host disease following allogeneic bone marrow transplantation. 
  • Graft versus host disease-related secretory immunoglobulin A deficiency in bone marrow transplant recipients. Findings in labial saliva. 
  • Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. 
  • Graft-v-host disease is associated with autoimmune-like thrombocytopenia. 
  • Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. 
  • Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. 
  • Graft-versus-host disease prevention by rapamycin: cellular mechanisms. 
  • Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. 
  • Graft-versus-host disease: allo- and autoimmunity after bone marrow transplantation. 
  • Graft-versus-host disease: the viewpoint from the donor T cell. 
  • Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. 
  • Graft-versus-leukemia in the rat--the antileukemic efficacy of syngeneic and allogeneic graft-versus-host disease. 
  • Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. 
  • Growth and development following marrow transplantation for leukemia. 
  • Growth hormone accelerates immune recovery following allogeneic T-cell-depleted bone marrow transplantation in mice. 
  • Growth patterns and gastrointestinal symptoms in pediatric patients after hematopoietic stem cell transplantation. 
  • HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group. 
  • Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia. 
  • Haploidentical hematopoietic cell transplantation. 
  • Hematopoietic Stem Cell Transplantation for CD40 Ligand Deficiency: Single Institution Experience. 
  • Hematopoietic cell transplantation for Chediak-Higashi syndrome. 
  • Hematopoietic chimerism in sheep and nonhuman primates by in utero transplantation of fetal hematopoietic stem cells. 
  • Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. 
  • Hematopoietic stem cell transplantation for complete IFN-gamma receptor 1 deficiency: a multi-institutional survey. 
  • Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. 
  • Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. 
  • Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. 
  • Hematopoietic stem-cell transplantation. 
  • Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. 
  • Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. 
  • Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. 
  • High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. 
  • Human Mesenchymal Stem Cell-Educated Macrophages Are a Distinct High IL-6-Producing Subset that Confer Protection in Graft-versus-Host-Disease and Radiation Injury Models. 
  • Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. 
  • Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. 
  • IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. 
  • Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. 
  • Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. 
  • Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. 
  • Immunoglobulin therapy in bone marrow transplantation. 
  • Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. 
  • Immunomodulation in stem-cell transplantation. 
  • Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. 
  • Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease. 
  • Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. 
  • Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD. 
  • In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. 
  • Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. 
  • Incompatible bone-marrow transplantation in lymphopenic immunologic deficiency. Circumvention of fatal graft-versus-host disease by immunologic enhancement. 
  • Increased BCR responsiveness in B cells from patients with chronic GVHD. 
  • Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. 
  • Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. 
  • Infections diagnosed in the first year after pediatric stem cell transplantation. 
  • Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. 
  • Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. 
  • Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. 
  • Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. 
  • Innate immune activation by the viral PAMP poly I:C potentiates pulmonary graft-versus-host disease after allogeneic hematopoietic cell transplant. 
  • Innate immune activation potentiates alloimmune lung disease independent of chemokine (C-X-C motif) receptor 3. 
  • International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I). 
  • Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. 
  • Intestinal and hepatic complications of human bone marrow transplantation. Part I. 
  • Intestinal and hepatic complications of human bone marrow transplantation. Part II. 
  • Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. 
  • Intravenous IgG to prevent graft-versus-host disease after bone marrow transplantation. 
  • Intravenous immune globulin prophylaxis in recipients of a marrow transplant. 
  • Introduction to a symposium on sickle cell anemia: current results of comprehensive care and the evolving role of bone marrow transplantation. 
  • L-selectin is dispensable for T regulatory cell function postallogeneic bone marrow transplantation. 
  • Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults. 
  • Late complications after marrow transplantation. 
  • Late complications of allogeneic and autologous marrow transplantation. 
  • Location, location, location: regional immune mechanisms critically influence rejection. 
  • Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. 
  • Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. 
  • Long-term complications of bone marrow transplantation. 
  • Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. 
  • Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. 
  • Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. 
  • Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. 
  • Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. 
  • Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. 
  • Long-term outcome after marrow transplantation for severe aplastic anemia. 
  • Long-term outcome of non-ablative booster BMT in patients with SCID. 
  • Long-term survival and cure after marrow transplantation for congenital hypoplastic anaemia (Diamond-Blackfan syndrome). 
  • Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. 
  • Longitudinal analysis of T-cell receptor variable beta chain repertoire in patients with acute graft-versus-host disease after allogeneic stem cell transplantation. 
  • Longterm followup and quality of life after hematopoietic stem cell transplantation. 
  • Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. 
  • Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. 
  • Marrow transplant experience for children with severe aplastic anemia. 
  • Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease. 
  • Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience. 
  • Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. 
  • Marrow transplantation for aplastic anemia. 
  • Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. 
  • Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. 
  • Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. 
  • Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. 
  • Marrow transplantation for severe aplastic anemia and thalassemia major. 
  • Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty "untransfused" patients. 
  • Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. 
  • Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. 
  • Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. 
  • Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. 
  • Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model. 
  • Memory T cells. 
  • Memory T cells: A helpful guard for allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease. 
  • Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. 
  • Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? 
  • MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. 
  • Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months. 
  • Minors come of age: Minor histocompatibility antigens and graft-versus-host disease. 
  • Mixed leukocyte culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia. 
  • Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD. 
  • Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. 
  • Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. 
  • Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. 
  • Myasthenia gravis after allogeneic bone marrow transplantation: relationship to chronic graft-versus-host disease. 
  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. 
  • Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. 
  • Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. 
  • Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. 
  • NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. 
  • Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy. 
  • New developments in allotransplant immunology. 
  • New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. 
  • Non-pharmacologic approaches to graft-versus-host prevention. 
  • Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia. 
  • Nonmyeloablative allogeneic stem cell transplantation using alternative donors. 
  • Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. 
  • Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice. 
  • Novel Scoring Criteria for the Evaluation of Ocular Graft-versus-Host Disease in a Preclinical Allogeneic Hematopoietic Stem Cell Transplantation Animal Model. 
  • Novel mechanism of rapamycin in GVHD: increase in interstitial regulatory T cells. 
  • Novel role for surfactant protein A in gastrointestinal graft-versus-host disease. 
  • Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. 
  • Ocular manifestations of graft-v-host disease. 
  • Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. 
  • One-unit versus two-unit cord-blood transplantation for hematologic cancers. 
  • Oral beclomethasone therapy for recurrent small bowel allograft rejection and intestinal graft-versus-host disease. 
  • Oral manifestations of chronic graft-v-host disease. 
  • Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. 
  • Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. 
  • Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. 
  • Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. 
  • Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis. 
  • Outcomes among 562 recipients of placental-blood transplants from unrelated donors. 
  • Outcomes of 122 diverse adult and pediatric cord blood transplant recipients from a large cord blood bank. 
  • Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. 
  • Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. 
  • Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. 
  • Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy. 
  • PD-L1 serves as a double agent in separating GVL from GVHD. 
  • PG27, an extract of Tripterygium wilfordii hook f, induces antigen-specific tolerance in bone marrow transplantation in mice. 
  • Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. 
  • Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. 
  • Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. 
  • Pathophysiologic mechanisms of acute graft-vs.-host disease. 
  • Pathophysiology and treatment of graft-versus-host disease. 
  • Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. 
  • Perspective: research highlights at the Duke University center for AIDS research. Immunoreconstitution in HIV infection: the role of the thymus. 
  • Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. 
  • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. 
  • Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. 
  • Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. 
  • Photoinactivation of lymphohemopoietic cells: studies in transfusion medicine and bone marrow transplantation. 
  • Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. 
  • Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. 
  • Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease. 
  • Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. 
  • Polymyositis as a manifestation of chronic graft-versus-host disease. 
  • Polymyositis as a manifestation of chronic graft-versus-host disease. 
  • Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. 
  • Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. 
  • Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. 
  • Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. 
  • Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. 
  • Prevalence of nutrition-related problems among long-term survivors of allogeneic marrow transplantation. 
  • Prevention and treatment of graft-versus-host disease. 
  • Prevention of GVHD without losing GVL effect: windows of opportunity. 
  • Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion. 
  • Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. 
  • Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. 
  • Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. 
  • Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. 
  • Progress in graft-versus-host disease. 
  • Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. 
  • Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. 
  • Prophylaxis and treatment of acute graft-versus-host disease. 
  • Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. 
  • Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. 
  • Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants. 
  • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. 
  • Protective role of T-bet and Th1 cytokines in pulmonary graft-versus-host disease and peribronchiolar fibrosis. 
  • Providing personalized prognostic information for adult leukemia survivors. 
  • Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. 
  • Radiographic features of esophageal involvement in chronic graft-vs.-host disease. 
  • Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. 
  • Rapamycin suppression of host-versus-graft and graft-versus-host disease in MHC-mismatched rats. 
  • Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. 
  • Rapidly progressive air-flow obstruction in marrow transplant recipients. Possible association between obliterative bronchiolitis and chronic graft-versus-host disease. 
  • Recognition, incidence, and management of oral graft-versus-host disease. 
  • Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. 
  • Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. 
  • Recovery of in vivo cellular immunity after human marrow grafting. Influence of time postgrafting and acute graft-versus-host disease. 
  • Recruitment of Donor T Cells to the Eyes During Ocular GVHD in Recipients of MHC-Matched Allogeneic Hematopoietic Stem Cell Transplants. 
  • Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation. 
  • Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. 
  • Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002). 
  • Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation. 
  • Regulating regulatory T cells. 
  • Rejection of canine cardiac allografts. 
  • Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. 
  • Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors. 
  • Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. 
  • Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. 
  • Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. 
  • Reversible leukoencephalopathy associated with graft-versus-host disease: MR findings. 
  • Review of chronic graft-versus-host disease in children after allogeneic stem cell transplantation: nursing perspective. 
  • Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review. 
  • Risk factors for acute GVHD and survival after hematopoietic cell transplantation. 
  • Risk factors for acute graft-versus-host disease associated with cyclosporine and methotrexate prophylaxis. 
  • Risk factors for airflow obstruction in recipients of bone marrow transplants. 
  • Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. 
  • Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. 
  • Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. 
  • Role of C-C motif ligand 2 and C-C motif receptor 2 in murine pulmonary graft-versus-host disease after lipopolysaccharide inhalations. 
  • Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. 
  • Science of composite tissue allotransplantation. 
  • Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. 
  • Second marrow infusion for poor graft function after allogeneic marrow transplantation. 
  • Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. 
  • Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. 
  • Secondary failure of platelet recovery after hematopoietic stem cell transplantation. 
  • Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting. 
  • Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. 
  • Severe combined immunodeficiency with natural killer-cell predominance: abrogation of graft-versus-host disease and immunologic reconstitution with HLA-identical bone marrow cells. 
  • Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors. 
  • Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. 
  • Spontaneous factor VIII inhibitor occurring in association with chronic graft-versus-host disease. 
  • Stem-cell transplantation for sickle cell disease. 
  • Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. 
  • Supportive care of the marrow transplant recipient: the Seattle Experience. 
  • Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. 
  • Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. 
  • T-Cell recovery in adults and children following umbilical cord blood transplantation. 
  • Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. 
  • Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. 
  • Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. 
  • Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. 
  • Thalidomide as salvage therapy for chronic graft-versus-host disease. 
  • The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. 
  • The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review. 
  • The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. 
  • The Knife's Edge of Tolerance: Inducing Stable Multilineage Mixed Chimerism but With a Significant Risk of CMV Reactivation and Disease in Rhesus Macaques. 
  • The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. 
  • The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success. 
  • The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. 
  • The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. 
  • The effect of natural killer cell killer Ig-like receptor alloreactivity on the outcome of bone marrow stem cell transplantation for severe combined immunodeficiency (SCID). 
  • The human bone marrow as an immunoregulatory organ. 
  • The management of chronic graft-versus-host disease. 
  • The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. 
  • The pathophysiology and treatment of graft-versus-host disease. 
  • The role of adenotonsillectomy in graft-versus-host disease. 
  • The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease. 
  • The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. 
  • The use of umbilical cord blood in mismatched related and unrelated hemopoietic stem cell transplantation. 
  • Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. 
  • Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. 
  • Tissue and tumor mosaicism of the myotonin protein kinase gene trinucleotide repeat in a patient with multiple basal cell carcinomas associated with myotonic dystrophy. 
  • Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. 
  • Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. 
  • Transfer of specific immunity in marrow recipients given HLA-mismatched, T cell-depleted, or HLA-identical marrow grafts. 
  • Transfusion effect on graft-versus-host disease and leukemic relapse in HLA-matched bone marrow transplantation. 
  • Transfusions shortly before HLA-matched marrow transplantation for leukemia are associated with a decrease in chronic graft-versus-host disease. 
  • Transplantation of fetal hematopoietic stem cells in utero: the creation of hematopoietic chimeras. 
  • Transplantation of the entire small bowel in inbred rats using cyclosporine. 
  • Transplantation outcomes for severe combined immunodeficiency, 2000-2009. 
  • Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. 
  • Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. 
  • Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. 
  • Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. 
  • Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. 
  • Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. 
  • Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. 
  • Treatment of marrow graft recipients with thymopentin. 
  • Treatment of non-Hodgkin's lymphoma with chemoradiotherapy and allogenic marrow transplantation. 
  • Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. 
  • Two Cases and a Review of Graft-Versus-Host Disease and the Role of Hepatitis C Treatment in Liver Transplant Patients. 
  • Two cases of transfusion-associated graft-vs-host disease after open heart surgery. 
  • Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation. 
  • Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. 
  • Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). 
  • Umbilical cord blood: a novel alternative source of hematopoietic stem cells for bone marrow transplantation. 
  • Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. 
  • Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial. 
  • Unrelated donor marrow transplantation in children. 
  • Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. 
  • Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. 
  • Unrelated placental blood in marrow transplantation. 
  • Unrelated umbilical cord blood transplantation in adult patients. 
  • Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. 
  • Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease. 
  • Use of thymic grafts or thymic factors to augment immunologic recovery after bone marrow transplantation: brief report with 2 to 12 years' follow-up. 
  • Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. 
  • Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. 
  • What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? 
  • You cannot improve what you do not measure. 
• 

  Keywords of People

  • Barfield, Raymond Carlton, Professor of Pediatrics, Duke Science & Society
  • Buckley, Rebecca Hatcher, James Buren Sidbury Professor of Pediatrics, in the School of Medicine, Immunology
  • Cardones, Adela Rambi Guanco, Associate Professor of Dermatology, Dermatology
  • Chen, Jun, Associate Professor of Medicine, Duke Cancer Institute
  • Craciunescu, Oana, Associate Professor of Radiation Oncology, Radiation Oncology
  • Halabi, Susan, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology
  • Parikh, Suhag H., Associate Professor of Pediatrics, Pediatrics, Blood and Marrow Transplantation
  • Pastva, Amy Martha, Assistant Professor in Orthopaedic Surgery, Cell Biology
  • Tsalik, Ephraim, Associate Professor of Medicine, Molecular Genetics and Microbiology